The data on insulin secretion, insulin sensitivity, and glucose homeostasis were confirmed in the phase II clinical study (clinical trials registration number NCT03131687) (62)
[DOI] [PMC free article] [PubMed] [Google Scholar] 58.Crown J., Sablin M.-P., Corts J., Bergh J., Im S.-A., Lu Y.S., Martnez N., Neven P., Lee K.S., Morales S., et al
and the proportion of patients achieving body weight loss of 5-10% [3]
According to literature comparisons, while both peptides demonstrate GH-releasing properties, the depth of Sermorelin research across multiple study populations exceeds that currently available for Ipamorelin
Unlike some medications that produce rapid, noticeable changes, GLP-1 receptor agonists work gradually, and their full therapeutic effects develop over several weeks
However, individual tolerance varies based on genetic factors, overall health, medication dose, and liver function